Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dollars, gaining the rights to EB-001A, the investigational botulinum neurotoxin type E formulation. EB-001A, currently in phase 2 trials, is characterized by a rapid onset of action of about 24 hours and a short duration of effect of about two to four weeks. Aclaris Therapeutics has been increasing its education to physicians, releasing a new video series featuring dermatologist Dr. Kavita Mariwala. Aclaris markets Eskata, the only product FDA approved for topical treatment of seborrheic keratosis or SK. Sebacia Microparticles are now FDA-cleared for use in the treatment of mild to moderate inflammatory acne.